337 related articles for article (PubMed ID: 35612829)
41. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.
Schauer F; Rafei-Shamsabadi D; Mai S; Mai Y; Izumi K; Meiss F; Kiritsi D
Front Immunol; 2022; 13():953546. PubMed ID: 35936009
[TBL] [Abstract][Full Text] [Related]
42. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review.
Brown AM; Masterson W; Lo J; Patel AB
Dermatitis; 2023; 34(3):201-208. PubMed ID: 34405836
[TBL] [Abstract][Full Text] [Related]
43. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
44. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
45. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
46. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
47. Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
Sabaté Ortega J; Fort Culillas R; Escoda Garcia M; Vásquez-Dongo CA; Sala González N
Curr Oncol; 2023 Aug; 30(9):7802-7809. PubMed ID: 37754481
[TBL] [Abstract][Full Text] [Related]
48. Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.
Wat M; Mollanazar NK; Ellebrecht CT; Forrestel A; Elenitsas R; Chu EY
J Cutan Pathol; 2022 Nov; 49(11):978-987. PubMed ID: 36054729
[TBL] [Abstract][Full Text] [Related]
49. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
50. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
51. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M; Accorinti M; Romagnuolo M; Marzano A; Di Zenzo G; Moro F; Antiga E; Maglie R; Cozzani E; Parodi A; Gasparini G; Sollena P; De Simone C; Caproni M; Pisano L; Fattore D; Balestri R; Sena P; Vezzoli P; Teoli M; Ardigò M; Vassallo C; Michelerio A; Satta RR; Dika E; Melotti B; Ribero S; Quaglino P
Front Med (Lausanne); 2023; 10():1208418. PubMed ID: 37547602
[TBL] [Abstract][Full Text] [Related]
52. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
53. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
54. Sclerosing mesenteritis following immune checkpoint inhibitor therapy.
Kuang AG; Sperling G; Liang TZ; Lu Y; Tan D; Bollin K; Johnson DB; Manzano JM; Shatila M; Thomas AS; Thompson JA; Zhang HC; Wang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9221-9227. PubMed ID: 37195298
[TBL] [Abstract][Full Text] [Related]
55. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors.
Fernández-Ruiz M
Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):67-73. PubMed ID: 36285862
[TBL] [Abstract][Full Text] [Related]
57. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Chen K; Sun B
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
[TBL] [Abstract][Full Text] [Related]
58. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
59. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
60. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.
Wang F; Shi X; Yu X; Yang Y
Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
